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I. Introduction
Alarmins are endogenous mediators of innate immunity. They are rapidly released in response to infection or tissue 
injury. In addition, they they are rapidly released from non programmed cell death but are not released from apoptotic cells. 
Alarmins recruit immune system and directly or indirectly promote adaptive immune responses. On the basis of their unique 
activities  they  have  been  called  „alarmins”  molecule.  Innate  immune  mediators  possessing  alarmin  activity  include 
defensins, cathelicidin, eosinophil-derived neurotoxin (EDN) and High Mobility Group Box Protein 1 (HMGB1).
Defensins are antimicrobial peptide components of the innate host defense system. The human defensins are a  
family of six cysteine 3–4-kD cationic peptides with a characteristic fold that is common to the two subfamilies, α- and β-
defensins, despite a difference in the connectivity of their disulfide bonds.
In humans, six human α-defensins have been identified. Four of them, human neutrophil proteins – HNP 1-4 -, are mainly 
produced by granulocytes. Human α-defensin 5 (HD5) and human α-defensin 6 (HD6) are present in intestinal Paneth cells. 
Human β-defensins are expressed predominantly in epithelial tissues. Although more than 90 human defensins have been 
identified by gene-based searches, the function of six human β−defensin (hBD1-6) are to known, they are expressed mainly 
by epithelial cells. The most prevalent expression of β-defensins is observed in the gastrointestinal and respiratory tracts; 
however, they are present throughout the entire epithelia. 
High  mobility group box 1  protein  (HMGB-1)  is  a  member  of  the nonhistone  chromatin-associated  proteins.  
Intracellular HMGB-1 has been studied previously for its roles in binding DNA; stabilizing nucleosome formation; as a  
general  transcription  factor  for  nucleolar  and  mitochondrial  RNA polymerases;  and  as  a  gene-  and  tissue-specific  
transcriptional regulator that can enhance transcription and/or replication. Extracellular HMGB-1 was recently implicated as 
a “late” mediator of delayed endotoxin lethality. HMGB-1 levels were increased significantly in critically ill patients with 
sepsis.  Extracellular  HMGB-1  might  play  a  mediator  role  in  the  setting  of  inadequate  tissue  perfusion.  Other  pro-
inflammatory mediators of endotoxemia that mediate similar pathological effects (e.g.,  TNF and IL-1) also function as 
potent stimulators of monocyte cytokine release in order to amplify and extend the “cytokine cascade”. Accordingly, it  
plausible that HMGB-1 might also function to stimulate monocytes to release TNF and other pro-inflammatory cytokines.
Helicobacter  pylori  infection  in  the  stomach can  be  found in  more  than  half  of  the  world’s  population.  The 
bacterium induces gastric inflammation, and the diseases that can follow this infection include chronic gastritis, peptic  
ulcers and gastric cancer.  In the stomach, gastric epithelial cells constitutively express hBD-1, whereas hBD-2 is induced in 
response to pro-inflammatory cytokines or microbial infection. Recent reports have demonstrated that  H. pylori  infection 
induces hBD-2, whereas hBD-1 is thought to be expressed constitutively.
Crohn’s disease, a chronic, inflammatory disease of the intestinal mucosa, is a complex multifactorial disease, the  
pathogenesis of which is still not fully understood. A major advance towards a better understanding of the disease was the 
discovery of mutations in the NOD2 gene in approximately one-third of Crohn’s disease patients. NOD may be involved in  
signaling  cascade-mediated  defensin  expression,  and  therefore  an  impaired  defensin  synthesis  has  been  linked  to  the 
occurrence of Crohn’s disease. Thus, decreased defensin levels lead to a weakened intestinal barrier function to intestinal  
microbes and might be crucial in the pathophysiology of Crohn’s disease.
II. Aims
The aim of  our study was to investigate the role of defensin and HMGB1 as alarmins in multifactorial diseases,  
where the natural defense system and genetic factors may influence the consequences of infection and/or injury. 
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Therefore we investigated
The effect of  H. pylori on defensin-α (HNP1-3) production by human granulocytes
The role of hBD1 SNP in H. pylori induced gastritis
The role of hBD1 SNPs in the pathomechanism of Crohn's disease
The relevance of HMGB1 in the severity of acute pancreatitis
III. Patients and methods
Patients with H. pylori induced Gastritis and controls
150 H. pylori-positive patients with chronic active gastritis included the study. Biopsy specimens were taken during 
upper gastrointestinal endoscopy from adjacent sites of the gastric antrum and corpus for histology. The 100 members of the 
control  population for  mutation analysis  were  age-  and gender-matched serologically  H. pylori-positive healthy blood 
donors without gastric or duodenal symptoms. 
Patients with Crohn’s disease and controls
190 unrelated patients with Crohn's disease were investigated. The diagnosis was based on the Lennard-Jones 
criteria. The disease phenotype (age at onset, duration, location and behavior) was determined according to the Vienna  
Classification.  The control group for mutation analysis consisted of 95 age- and gender-matched healthy blood donors.
Patients with Acute pancreatitis and controls
Blood samples were obtained from 62 patients with acute pancreatitis. All patients were classified as having mild 
or severe pancreatitis according to the original criteria of Ranson . Patients with fewer than three positive prognostic signs  
(n=32) were considered to have mild pancreatitis; while those with three or more positive prognostic signs (n=30) were 
classified into the severe pancreatitis group. For comparison 20 patients with sepsis of different origin,  in the surgical 
intensive care unit were enrolled in the study. The control cohort considered of  a random, unrelated population of 20  
healthy blood donors.
Genotyping procedures 
For the examination of human beta-defensin polymorphisms leukocyte DNA purified from peripheral blood was 
isolated using the High Pure PCR Template Preparation Kit in accordance with the manufacturers’ instructions (Roche  
Diagnostic GmbH, Mannheim, Germany). Genotyping was done using Custom TaqMan SNP Genotyping Assays (Applied 
Biosystems, Foster City, Calif., USA). In order to verify the given data, restriction fragment length polymorphism analysis  
(RFPL) was performed.
Bacterial strains and culture
The H. pylori 26695 CagA+ Vac A+ strain was used, which was generously donated by D.E. Berg (Department of 
Molecular Biology and Genetics, Washington University Medical School, St. Louis, USA). Bacteria were maintained on 
Brain Heart agar containing 10% sheep blood, and incubated in a microaerophilic atmosphere. Inocula for co-culturing were 
diluted from suspensions that had been prepared from 72-h subcultures and adjusted by comparison of the absorbance with 
standards. The cag pathogenicity island (PAI)-negative Tx30a strain of ATCC 51932 was cultivated similarly. For co-culture 
experiments, both strains were used at a multiplicity of infection (MOI) of 100.
Cells
The human gastric cell line AGS was maintained in RPMI 1640 culture medium supplemented with 10% heat 
inactivated foetal calf serum (FCS), (GIBCO), 2mM glutamine, 100 U/ml penicillin, 100 mg/ml streptomycin. Cells (106)  
were seeded into 6-well tissue culture plates (COSTAR) and maintained at 37oC in 5% CO2. Confluent cells were left  
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uninfected, or were infected with H. pylori at a MOI of 100.
Inhibitor studies
AGS cells were pretreated with ERK activation inhibitor peptide (Calbiochem 328005) at 50 mg/ml for 30 min  
prior to and during bacterial stimulation.
RNA isolation and PCR amplification
Total RNA was isolated with Trizol reagent (Invitrogen, Carlsbad, Calif., USA.) according to the manufacturer's 
instructions. RNA concentration was determined by the A260 value of the sample. Complementary DNA (cDNA) was  
generated from 1 µg total RNA using high-capacity cDNA reverse transcription kits (Applied Biosystems) in a final volume 
of 20  µl. Real-time reverse transcription PCR (RT-PCR) analyses were performed in a fluorescence temperature cycler 
(LightCycler; Roche Diagnostics GmbH) in accordance with the manufacturer’s instructions. After reverse transcription,  
amplification was carried out using LightCycler FastStart DNA Master PLUS SYBR Green I mix (Roche Diagnostics). All  
quantifications were normalized to the housekeeping GAPDH gene. Relative expression is given as a ratio between target  
gene and GAPDH gene expression.
Isolation of granulocytes and mononuclear cells
Peripheral  white  blood  cells  were  prepared  from  EDTA-anticoagulated  venous  blood  samples  from  healthy 
volunteers by density gradient purification. Peripheral blood mononuclear cells were separated by Ficoll Hypaque (Sigma 
Chemicals) density gradient centrifugation. Human polymorphonuclear granulocytes were isolated by the same density 
gradient centrifugation. Purified neutrophils were resuspended in RPMI 1640 medium supplemented with 10 % FCS (fetal 
calf serum) to achieve final concentration of 1 × 106 cells/ml. Experimental cultures (1 × 106/ml) were incubated without or 
with 108/ ml  Helicobacter pylori 26695 for 1–4 h, following which the cells were centrifuged and processed for flow 
cytometry. Cell supernatants were tested for HNP1-3 content by ELISA.
Whole blood incubation method
Venous blood samples from healthy blood donors  were incubated in the presence or absence of H. pylori for 4 h. 
Following the incubation period the cells were centrifuged and the supernatants were tested for HNP1-3 content by ELISA.
Flow cytometric analysis
Granulocytes and mononuclear cells were  labeled with monoclonal mouse anti human defensin (clone DEF3;  
Serotec  Ltd.  UK).  As  a  secondary  antibody FITC  conjugated  goat  anti  –  mouse  IgG  (SIGMA) was  applied.   Flow  
cytometric analysis was performed thereafter with a FACStar plus fluorescence-activated cell sorter (Becton-Dickinson) at  
488 nm excitation to estimate intracellular α-defensin in peripheral granulocytes and mononuclear cells.
HNP1-3 ELISA
The HNP 1–3 ELISA kit was obtained from HyCult Biotechnology, The Netherlands. Plasma samples of whole 
blood  cultures  and  supernatants  of  granulocytes  and  mononuclear  cells  were  analysed  with  standard  measurements, 
according  to  the  manufacturer’s  instructions.  ELISA plates  were  measured  on  an  Anthos  2010  Reader  at  450  nm. 
Concentration of HNP1–3 in plasma and supernatants were calculated according to a standard curve.
LDH assay
To determine whether the tested granulocytes has been damaged during prolonged cultivation with or without H. 
pylori, which could lead to α-defensin release, 200 µl samples of the supernatants were assayed for lactate dehydrogenase 
activity using LDH kit Cyto Tax PROMEGA.
HMGB ELISA
Plasma  HMGB1  concentration  were  determined   with  an  established  ELISA kit  (Shino-Test-Corp.,  Japan) 
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according to the instructions of the manufacturer.
sRAGE ELISA
The sRAGE antigen in the plasma was determined by ELISA (R&D Systems, Wiesbaden, Germany) according to 
the instructions of the manufacturer.
Measurement of Plasma DNA
Plasma  DNA levels  were  estimated  by the  quantitative  PCR method using  primers  for  the  β-globin  gene,  a 
housekeeping gene. 
Statistical analyses
The α-defensin levels in the supernatants of H. pylori infected and control cell cultures were compared by using the 
Student t test, and statistical significance was defined as p< 0.05. Data are presented as means +- S.E.M.
Statistical analyses for comparison of genotype frequencies between groups were performed using the x2 test, and the Fisher 
exact test if one cell had n=5. The probability level of p<0.05 indicated statistical significance. The relationship between 
genotypes and disease severity is presented as the odds ratio (OR), with a 95% confidence interval (95% CI). The genotype  
frequencies for each polymorphism were tested for deviation from the Hardy- Weinberg equilibrium by means of the x2 test,  
with one degree of freedom used.  The levels of HMGB1, sRAGE and circulating DNA in the plasma were compared by 
means  of  one-way  ANOVA.  The  Bonferroni  test  was  used  for  post  hoc  pair-wise  multiple  comparisons.  Statistical 
calculations were done with the Graph Pad Prism 5 (Graph Pad Software Inc., San Diego, Calif., USA) statistical program.
IV. Results
IV.1. Helicobacter pylori induces the release of α-defensin by human granulocytes
Stimulation of granulocytes with H. pylori for 4 h resulted in a decrease in intracellular staining (m. f. i. 250). This 
decrease was due to the extracellular release of  α-defensin; it was proved by measuring the  α-defensin levels in the cell 
supernatants. Following a 4 h incubation with  H. pylori (108),  granulocytes produced 75713 +-8376 pg/ml  α-defensin 
which was significantly higher than the amount released during the 4-h incubation from the non-stimulated cells (5200 +-
2521 pg/ml). The α-defensin levels in the supernatants increased parallel with the decrease in the intracellular α-defensin 
content determined by flow cytometry. Induction of mononuclear cells (1 × 106/ml) with H. pylori (108/ml) did not result in 
a significant change in the intracellular staining, i.e. α-defensin content of the cells (m. f. i.= 34.5).
IV.2.  Potential role of human β-defensin 1 in Helicobacter pylori-induced gastritis
The frequency of AA homozygotes was significantly higher in the group of patients with H. pylori induced gastritis 
(25%) than in the controls (11%) ( p=0.005; OR2.745, 95% CI=1.3275.677). When the patients were stratified according to 
the density of H. pylori in the biopsy samples (i.e. mild colonization, or severe colonization) a significant difference in the 
frequency  of GA heterozygotes was observed between the controls and the patients with severe  H. pylori colonization 
(  p=0.005; OR2.250,  95% CI=1.2863.936).  The frequency of  AA heterozygotes  among patients with severe  H. pylori  
colonization  was  26%,  with  an  OR  of  2.868.   The  genotypic  distribution  of  the  hBD1  C-44G  and  hBD1  C-20  G  
polymorphisms was no significant difference in genotype distribution between the patients overall and the healthy controls  
in any of these two SNPs.
A time-dependent increase in hBD-1 mRNA expression was observed in AGS cells over a 48-h incubation period.  
Infection by the cag PAI-negative strain showed expression of hBD-1 to a similar extent as observed for the cag A-positive  
H. pylori 26695 strain. There was a significant ( p=0.029) reduction in the expression of hBD-1 following pretreatment of  
AGS cells with the ERK activating inhibitor.
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IV.3. Human β-defensin polymorphisms in patient with Crohn's disease
There was no significant difference in genotypic distribution (G-20A) between the Crohn’s disease patients overall 
and the healthy controls. When the patients were stratified according to localization of the disease i.e. ileal, ileocolonic, or  
colonic a  significant  difference was observed between the controls  and the patients  with colonic localization (x2 test,  
p=0.043) but not between the controls and the patients with ileal or even ileocolonic localization of the disease. At  the  
distribution of hBD1 C-44 G genotypes there was a lower frequency of the GG genotype among the patients with Crohn’s  
disease as compared with the controls. The difference concerning this genotype between patients with ileal localization was  
not significant, whereas it was marginally significant among the patients with colonic localization (p=0.06), and statistically 
significant  among  patients  with  ileocolonic  localization.  There  were  no  significant  differences  in  the  hBD1  G-52A 
genotypic distributions between the patients with Crohn’s disease and healthy controls.
IV.4.  Plasma Concentrations  of  High Mobility  Group Box Protein 1  (HMGB1),  sRAGE  and Circulating  DNA in  
Patients with Acute Pancreatitis
The plasma HMGB1 concentration was significantly higher in the patients with severe acute pancreatitis than in the 
healthy controls  (p<0,001)  or  in  patients  with  mild  pancreatitis  (p=<0,001).  The  highest  HMGB1 concentration  were  
detected in the plasma of patients infected necrosis (17,5-42 ng/ml, n=8) The circulating sRAGE levels were compared in 
the patients with mild and severe acute pancreatitis, in the patients with sepsis, and in the healthy controls .  The highest 
sRAGE level was detected in patients with sepsis.  The plasma sRAGE level proved to be inversely associated with plasma 
HMGB1 level in patients with acute pancreatitis. In contrast, for the septic patients a positive correlation was observed 
between the plasma sRAGE and HMGB1 concentrations. The highest plasma DNA concentration was measured in the 
patients with sepsis.  The plasma DNA concentration was significantly higher than the controls level also in the case of the  
patients with severe acute pancreatitis. No significant difference was observed in plasma DNA concentrations between the 
patients with mild pancreatitis and healthy controls.
V. Discussion
V.1.Helicobacter pylori induces the release of α-defensin by human granulocytes
Our experiments demonstrated the α-defensin inducing capacity of H. pylori not only in the case of purified granulocytes, 
but also when a whole blood incubation method was applied. In the peripheral blood the neutrophil granulocytes are the  
main source of  α-defensin, and we therefore suggest that  the elevation of the level of  α−defensin following  H. pylori  
infection is mainly due to the activity of the granulocytes. Monocytes, immature dendritic cells, lymphocytes also have been 
reported to contain α-defensin. Our flow cytometric analysis revealed intracellular α-defensin staining in mononuclear cells 
but with much lower intensity was much less than for the granulocytes, and only 23 % of the mononuclear cells were  
stained positively intracellularly. A low basal level of α-defensin was measured in the supernatants of these cells, but here 
was no significant increase in the level following the incubation of mononuclear cells with  H. pylori.  Accordingly,  we 
conclude that the α-defensin in the supernatants of whole blood cultures can be regarded as products of the granulocytes. 
This is all the more likely, if it is borne in mind, that the neutrophils account for the highest number of leukocytes in the  
peripheral blood. Whole blood culturing method is a reliable method with which to investigate the effects of activating  
agents on granulocytes.
V.2. Potential role of human β-defensin 1 in Helicobacter pylori-induced gastritis
We investigated the relevance of three hBD1 SNPs in patients with  H. pylori  induced gastritis. In our study the 
analysis of hBD1 G-52 A genotypes revealed that  the AA and GA genotype comprises a higher risk of chronic active 
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gastritis among  H. pylori-infected subjects, with a higher rate of colonization with the bacteria. Although the functional  
impact is unclear, it is tempting to speculate that this mutation at the -52 untranslated region might cause a lower hBD-1  
expression in gastric epithelial cells with deficient function of human defensin. This could lead to increased colonization of 
H. pylori in the stomach, with ineffective clearance, and consequent inflammation. Additional functional studies will be  
necessary to establish the exact biological role of this SNP. No further significant differences were observed for the SNPs of  
hBD1 C-44 G and hBD1 C-20 G. Increased hBD-1 expression was likewise observed following infection of AGS cells with  
the cag PAI strain. In our experiments, however, not only the CagA-positive, but also the cag PAI-negative strain resulted in 
hBD-1 expression. Therefore it is tempting to speculate that, in contrast with hBD-2, the hBD-1 activation is possible in a  
NOD1-independent way. In contrast to hBD-2, hBD-3 expression was NOD1-independent, but EGFR and ERK pathway 
dependent.  H.  pylori infection  activates  ERK  and  MEK  kinases  in  AGS  gastric  epithelial  cells,  in  both  a  cag  PAI-
independent and cag PAI-dependent manner. In this way, ERK and MAP kinases are regulated during H. pylori infection 
through the use of secreted factors, and also in an epithelial contact-dependent manner in which  cag  PAI-positive strains 
exert the ability to induce higher levels of ERK and MEK phosphorylation. We suggest a potential role for this pathway in  
hBD-1  expression.  In  contrast  to  hBD-2,  it  seems  that  hBD-1  expression  could  also  be  NOD1 independent,  at  least 
independent on cag PAI, but ERK pathway dependent. This might be the reason for a 50% reduction in the expression of 
hBD-1 following the pretreatment of AGS cells with the ERK activation inhibitor prior to infection with H. pylori 26695. As 
the ERK pathway can be activated by the cag PAI-independent strain, we suggest a potential role of this pathway in hBD1 
expression in the presence of the Tx30a strain. Other signaling pathways that might be important in hBD-1 expression 
cannot be excluded.
V.3. Human β-defensin polymorphisms in patient with Crohn's disease
Ileal and colonic Crohn’s disease can be linked with a lowered defensin profile. We analysed the  genetic variation  
in the hBD1 gene in Crohn's disease. The analysis of hBD1 G-20A genotypes among patients with Crohn’s disease revealed  
that the GA genotype comprises a higher risk of colonic Crohn’s disease (OR2.393, 95% CI: 1.176 4.869). There was no 
correlation between this SNP and the ileal or ileocolonic form of the disease. The functional significance of this SNP resides  
in the formation of a nuclear factor-κB transcription factor-binding sequence, but the functional impact is unclear. As the 
colonic localization of the disease is connected with impaired hBD1 expression, it is tempting to speculate that this mutation 
might cause a lower hBD1 expression in colonic epithelial cells. Additional functional studies will be necessary to establish 
the exact biological role of this SNP. The present study has demonstrated that the distributions of C-44G (according to the 
initiation codon-based nomenclature), also known as the hBD1 668C/G genotype, were different in patients with Crohn’s  
disease and healthy controls, while the frequency of the GG genotype was significantly higher in the controls. This result  
indicates that the C-G mutation probably leads to strengthened hBD1 antimicrobial activity, which is less frequent among  
patients  with  Crohn’s  disease.  No further  significant  differences  were  observed  for  the SNPs when the  patients  were  
stratified according to behaviour of the disease or the extraintestinal manifestations. The only difference in genotypes was 
observed when patients were stratified as smokers and non-smokers. It is interesting that the correlation between genotype  
frequencies of SNPs of G-20A and C-44G was striking only among non-smokers. However, a significant difference between 
the smokers and the controls was not observed for the genotypes. We speculate that defensin SNP might basically influence  
the  susceptibility  to  Crohn’s  disease,  but  regarding  smoking  habits,  other  factors  might  superimpose  to  worsen  the  
genetically determined situation. This means that smoking increases the susceptibility to and severity of Crohn’s disease;  
moreover, smoking habit and disease location are contributory factors in this process.
V.4. Plasma Concentrations of High Mobility Group Box Protein 1 (HMGB1), sRAGE  and Circulating DNA in Patients  
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with Acute Pancreatitis
We found a  significant  elevation  of  the  HMGB-1 concentration  in  the  plasma  of  patients  with  severe  acute  
pancreatitis. We compared the results with the data on septic patients, as the elevation of HMGB1 level in sepsis is well  
documented. The HMGB1 level in the patients with severe acute pancreatitis was comparable  with the levels in septic 
patients,  and even more higher (however no statistically significantly).  In  acute pancreatitis  HMGB1 secretion can be 
induced by inflammatory cytokines, which play a definitive role in the pathomechanism of acute pancreatitis. In severe,  
necrotizing pancreatitis the passive release of HMGB1 from necrotic cells may be an additional source of HMGB1. This 
may be the reason for a significant difference in HMGB1 levels between patients with mild and severe form of disease.  
Infected pancreatic necrosis was diagnosed in 8 of the patients with severe acute pancreatitis. It  is noteworthy that the 
highest levels were measured in the plasma of these patients (17.5 – 42 pg/ml) very probably in consequence of the additive 
effects of inflammation, necrosis and infection. 
Extracellular HMGB1 regulates cells through RAGE and Toll like receptors reported an elevation in the level of sRAGE in 
septic patients. We likewise observed this in our septic patients, but there was an inverse correlation between the levels of 
sRAGE and HMGB1 in the patients with severe acute pancreatitis. We found, that the level of released sRAGE relates  
inversely to the HMGB1 level, but only in the case of acute pancreatitis. 
Thus it may be speculated, that the more HMGB1 there is in the circulation, the lower will be the level of sRAGE:in severe  
acute pancreatitis. The question arises whether the low level of  sRAGE is simply due to its consumption to bind HMGB1,  
or whether there are any other components which could decrease the level of sRAGE. The elevation of other  (as yet  
undefined) components in the circulation, that can suppress the amount of  soluble RAGE receptor can not be excluded. 
Whatever the reason, the relatively high HMGB1 levels relative to the low sRAGE levels  make the feedback mechanism  
less effective, and further enhance the inflammatory loop in acute pancreatitis. 
Our data  revealed,  that  the  circulating DNA significantly elevated  in  patients  with severe  pancreatitis,  or  in  sepsis.  A 
significant elevation was not observed in those with mild pancreatitis. Our data are in contrast with those of Bagul et al.,  
who found a decreased rather than an increased level of plasma DNA in severe acute pancreatitis. There may well be some 
methodological differences between  the two studies. First, our study involved the use of a real time quantitative PCR  
method  for  the  β-globin  gene,  which  is  a  widely  accepted  method.  We  applied  the  two-step  procedure  of  sample 
centrifugation, while Bagul et al. separated the plasma only with one centrifugation step at 2000 rpm. This could result in a  
high variation in DNA concentration, originating not only from cell the free DNA, but also from contaminating leukocytes.  
From the aspect that both inflammation and necrosis are involved in the pathogenesis in acute pancreatitis, a complex study  
of the levels of HMGB1, sRAGE, and plasma DNA might be informative in an evaluation of the effects of different levels  
of severity of acute pancreatitis.
Summary: Conclusions and potential significances
The major new findings of our experiments are as follows:
1. H. pylori induce α-defensin release from granulocytes which may well be important in local host response to H. 
pylori infection in gastroduodenal diseases.
2. The association of the higher frequency of the G-52 A SNP of hBD1 with chronic active gastritis, and the elevated  
level  of hBD-1 mRNA following  H. pylori infection draw attention to the importance of hBD-1 in  H. pylori  
infection. This indicates that not only the inducible, but also the constitutive form of hBD-1 plays a role in the  
development of chronic active gastritis following H. pylori infection.
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3. The  colonic Crohn’s disease could be due to defective  β-defensin 1 production. This means that  not only the 
inducible, but also the constitutive form of hBD1 plays a definitive role in the colonic localization of Crohn’s 
disease.
4. The circulating HMGB1 level was significantly higher in the patients with severe acute pancreatitis than in the 
healthy controls or the patients with mild pancreatitis, and the level of HMGB1 correlated inversely with that of 
sRAGE. The plasma DNA level was increased in severe acute pancreatitis. These observations underline the role of  
HMGB1 and its receptor in the pathogenesis of acute pancreatitis, and in the severity of the disease. Blockade of  
HMGB1 should be considered as possible future therapy in sepsis and severe acute pancreatitis.
ACKNOWLEDGEMENT
I would like to express my deep and sincere gratitude to my supervisor, Professor Dr. Yvette Mándi for supporting me 
during these past three years . Her wide knowledge and her logical way of thinking have been of great value for me. Her  
understanding, encouraging and personal guidance have provided a good basis for the present thesis. 
I thank all the members of the Department of Medical  Microbiology and Immunobiology, at the Faculty of Medicine, at the 
University of Szeged for their support and for creating a pleasant work-environment. I am especially thankful for the help  
from Dr. Ferenc Somogyvári, Dr. Péter Hofner and Dr. Zoltán Tiszlavicz, for the excellent technical assistance by Györgyi  
Müller, and for Zsuzsanna Rosztoczy for skilful administration.
I thank all my clinical partners particularly, Dr. Imre Ocsovszky at Department of Biochemistry, University of Szeged, Dr 
László Tiszlavicz at Department of Pathology, University of Szeged, Dr Zsuzsanna F. Kiss at First Department of Medicine 
University of Szeged, Dr. Péter László Lakatos, Dr. Péter Fuszek, Dr. János Papp, Dr. Simon Fischer, Dr Tamás Szamosi, at  
1st  Department  of  Medicine,  Semmelweis  University,  Budapest,  Dr.  László  Lakatos  at  1st  Department  of  Medicine,  
Csolnoky F. County Hospital, Veszprém, Dr. Ágota Kovács at 1st Department of Medicine, Erzsébet Hospital, Budapest, Dr. 
Annamária Szabolcs at First Department of Internal Medicine Faculty of Medicine, University of Szeged, Dr. Gyula Farkas 
at  Department of Surgery, Faculty of Medicine, University of Szeged for their help in providing me with patients samples  
and clinical data necessary for the experiments.
Finally, I am grateful to my husband, my son, my mother and father and my whole family for the love and untiring support 
during my PhD Studies and for making the whole work worthwhile.
Publications with results incorporated in the thesis:
I. Kocsis AK, Ocsovszky I, Tiszlavicz L, Tiszlavicz Z, Mándi Y.: 
Helicobacter pylori induces the release of alpha-defensin by human granulocytes.  Inflamm  Res.  2009 
May;58(5):241-7. 
IF:1,457
II. Kocsis AK, Kiss ZF, Tiszlavicz L, Tiszlavicz Z, Mándi Y.:
Potential role of human beta-defensin 1 in Helicobacter pylori- induced gastritis. 
Scand J Gastroenterol. 2009;44(3):289-95. 
IF:1,98
III.  Kocsis AK, Lakatos PL, Somogyvári F, Fuszek P, Papp J, Fischer S, Szamosi T, Lakatos L, Kovács A, 
Hofner P, Mándi Y.:
Association of beta-defensin 1 single nucleotide polymorphisms with Crohn's disease. 
9
Scand J Gastroenterol. 2008 Mar;43(3):299-307. 
IF:1,98
IV. Kocsis AK, Szabolcs A, Hofner P, Takács T, Farkas G, Boda K, Mándi Y.
Plasma concentrations of high-mobility group box protein 1, soluble receptor for advanced glycation end-
products and circulating DNA in patients with acute pancreatitis. 
Pancreatology. 2009;9(4):383-91. Epub 2009 May 19. 
IF:3,043
Total impact factor: 8,46
Publications not directly related to the thesis:
Tiszlavicz Z, Somogyvári F, Kocsis AK, Szolnoki Z, Sztriha LK, Kis Z, Vécsei L, Mándi Y. 
Relevance of the genetic polymorphism of NOD1 in Chlamydia pneumoniae seropositive stroke patients. 
Eur J Neurol. 2009 Nov;16(11):1224-9
IF:2,732
Tiszlavicz Z, Gyulai Z, Bencsik K, Szolnoki Z, Kocsis AK, Somogyvári F, Vécsei L, Mándi Y. 
RAGE gene polymorphisms in patients with multiple sclerosis. J Mol Neurosci. 2009 Nov;39(3):360-5
IF:2,061
 Papp M, Lakatos PL, Harsfalvi J, Farkas G, Palatka K, Udvardy M, Molnar T, Farkas K, Nagy F, Veres G, 
Lakatos L, Kovacs A, Dinya T, Kocsis A, Papp J; Hungarian IBD Study Group, Altorjay I. 
Mannose-binding lectin level and deficiency is not associated with inflammatory bowel diseases, disease 
phenotype, serology profile, and NOD2/CARD15 genotype in a large Hungarian cohort. Hum Immunol. 2010 
Jan 25
IF:3,061
Total impact factor: 7,854
Cumulative impact factor: 16,314
10
